Characterization of the Antiglioma Effect of the Oncolytic Adenovirus VCN-01

Despite the recent advances in the development of antitumor therapies, the prognosis for patients with malignant gliomas remains dismal. Therapy with tumor-selective viruses is emerging as a treatment option for this devastating disease. In this study we characterize the anti-glioma effect of VCN-01...

Descripción completa

Detalles Bibliográficos
Autores principales: Vera, Beatriz, Martínez-Vélez, Naiara, Xipell, Enric, Acanda de la Rocha, Arlet, Patiño-García, Ana, Saez-Castresana, Javier, Gonzalez-Huarriz, Marisol, Cascallo, Manel, Alemany, Ramón, Alonso, Marta M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4726573/
https://www.ncbi.nlm.nih.gov/pubmed/26808201
http://dx.doi.org/10.1371/journal.pone.0147211
Descripción
Sumario:Despite the recent advances in the development of antitumor therapies, the prognosis for patients with malignant gliomas remains dismal. Therapy with tumor-selective viruses is emerging as a treatment option for this devastating disease. In this study we characterize the anti-glioma effect of VCN-01, an improved hyaluronidase-armed pRB-pathway-selective oncolytic adenovirus that has proven safe and effective in the treatment of several solid tumors. VCN-01 displayed a significant cytotoxic effect on glioma cells in vitro. In vivo, in two different orthotopic glioma models, a single intra-tumoral administration of VCN-01 increased overall survival significantly and led to long-term survivors free of disease.

Ejemplares similares